Last updated on June 2019

Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)


Brief description of study

The purpose of this research is to determine whether giving severely injured adults a drug called tranexamic acid (TXA) as soon as possible after injury will improve their chances of survival and their level of recovery at six months.

After severe injury, a person may have uncontrolled bleeding that places them at high risk of bleeding to death. Coagulation (the formation of blood clots) is an important process in the body that helps to control blood loss. Up to a quarter of people that are severely injured have a condition called acute traumatic coagulopathy. This condition affects coagulation and results in the break down of blood clots (fibrinolysis) that can lead to increased blood loss and an increased risk of dying.

TXA is an anti-fibrinolytic drug that might help to reduce the effects of acute traumatic coagulopathy by preventing blood clots from breaking down and helping to control bleeding. In Australia, TXA is approved for use by the Therapeutic Goods Administration (TGA) to reduce blood loss or the need for blood transfusion in patients undergoing surgery (i.e. cardiac surgery, knee or hip arthroplasty). Recent evidence from a large clinical trial (CRASH-2) showed early treatment with TXA reduced the risk of death in severely injured patients, however the majority of patients involved in the study were injured in countries where prehospital care is limited and rapid access to lifesaving treatments is limited compared to that available in countries like Australia and New Zealand. It is unclear whether TXA will reduce the risk of death to the same degree when it is given alongside other lifesaving treatments that are available to patients soon after injury in these countries.

The hypothesis is that TXA given early to injured patients who are at risk of acute traumatic coagulopathy and who are treated in countries with systems providing advanced trauma care reduces mortality and improves recovery at 6-months after injury.

Clinical Study Identifier: NCT02187120

Find a site near you

Start Over

Hawke's Bay

Hastings, New Zealand
  Connect »

Waikato Hospital

Hamilton West, New Zealand
  Connect »

St John Ambulance

Albany, New Zealand
  Connect »

CareFlight

Northmead, Australia
  Connect »

The Alfred Hospital

Melbourne, Australia
  Connect »

Ambulance Victoria

Melbourne, Australia
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Gold Coast Hospital

Gold Coast, Australia
  Connect »

Flinders Medical Centre

Bedford Park, Australia
  Connect »

Middlemore Hospital

Auckland, New Zealand
  Connect »

Wellington Hospital

Wellington, New Zealand
  Connect »